{"id":"W2969960972","doi":"10.1016/j.jaci.2019.08.013","title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","year":2019,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Maruho; Chugai Pharmaceutical; LEO Pharma; AbbVie; Glenmark Pharmaceuticals; UCB Pharma; Galápagos; Amgen; Boehringer Ingelheim; Les Laboratories Pierre Fabre; Janssen Biotech; Santen; Novartis; Celgene; Kiniksa Pharmaceuticals; Beiersdorf; MedImmune; Sanofi; Regeneron Pharmaceuticals; Pfizer; Almirall; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Eczema Area and Severity Index; Placebo; Medicine; Atopic dermatitis; Randomized controlled trial; Dosing; Internal medicine; Gastroenterology; Adverse effect; Clinical endpoint; Severity of illness; Corticosteroid; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001324823,0.001639101,0.002908697,0.0003040513,0.0003849387,0.0009940545,0.0008921092,0.001303161,0.008294045],"category_scores_gemma":[0.0009907269,0.0007478779,0.001570386,0.0002436091,0.0009690555,0.001099734,0.0004237803,0.00270071,0.001197286],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007428387,"about_ca_system_score_gemma":0.001018802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001157094,"about_ca_topic_score_gemma":0.003129164,"domain_scores_codex":[0.9995839,0.0001979147,0.0000205586,0.00007761844,0.00003267819,0.00008724879],"domain_scores_gemma":[0.999553,0.0001051558,0.00007911112,0.00004202072,0.0000272604,0.0001934299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9694963,0.008722195,0.0008907143,0.0004238275,0.000834589,0.0000626637,0.0000514306,0.0003232519,0.004950448,0.0001518087,0.001134058,0.01295882],"study_design_scores_gemma":[0.9722894,0.02485537,0.001624161,0.0000133938,0.0001726475,0.00002978258,0.00001567871,0.0002027857,0.0001946011,0.00007812616,0.0005168645,0.000007092383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986362,0.00380405,0.0007866103,0.001057141,0.0005727937,0.003151455,0.001417612,0.0001372183,0.002711286],"genre_scores_gemma":[0.981901,0.002400279,0.001946662,0.001806987,0.0004503833,0.004147013,0.001738369,0.00004415352,0.005565051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008294045,"threshold_uncertainty_score":0.02774632,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01156842414867016,"score_gpt":0.3090482567785854,"score_spread":0.2974798326299152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}